Skip to content
Biodatica
Start free

TuHURA Biosciences, Inc.

Los Angeles, California

OncologyPhase IIIListed · HURA

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase III trial registered: Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

3mo agoTrial registeredApr 17, 2026Source filing (opens the source filing in a new tab)

Momentum

83no change

Momentum 83 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2/PHASE3 registered

    Dec 11, 2025

    Advanced Or Metastatic Merkel Cell Carcinoma · RECRUITING · sponsor: TuHURA Biosciences, Inc. · Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

    ClinicalTrials.gov · NCT06947928 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Jun 20, 2025

    Cutaneous Sarcoma · RECRUITING · sponsor: H. Lee Moffitt Cancer Center and Research Institute · Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma

    ClinicalTrials.gov · NCT07007273 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    May 28, 2021

    Merkel Cell Carcinoma, Neuroendocrine Carcinoma of the Skin, Trabecular Carcinoma of the Skin · ACTIVE_NOT_RECRUITING · sponsor: H. Lee Moffitt Cancer Center and Research Institute · Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

    ClinicalTrials.gov · NCT04869137 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources